CooperVision Notifies ECPs of Decision to Drop UPP for Biofinity Energys Lenses

PLEASANTON, Calif.—CooperVision, a unit of The Cooper Cos. (NYSE:COO), notified ECPs late last week that it was removing its Biofinity Energys contact lens product line from its Unilateral Pricing Policy (UPP) effective immediately. The move is a result of the “well-established [place] in the market” the lenses have achieved, the company said in a letter to eyecare professionals. In March, CooperVision announced that it was removing three other lens products from its UPP program: MyDay, clariti 1-day and Biofinity XR toric brands. It maintained UPP for Biofinity Energys at that time, as VMail reported. In a letter from CooperVision’s president,…

Novartis to Acquire Encore Vision, Developer of Eye Drop for Treating Presbyopia

BASEL, Switzerland—Novartis announced yesterday that it has entered into a definitive agreement to acquire Encore Vision, a privately-held company in Fort Worth, Texas, that has developed eye drops for treating presbyopia. The financial details of the transaction, which is subject to regulatory approval, were not disclosed. “There is a large need for innovative, effective and safe treatment options for people with presbyopia, and there is currently no disease-modifying treatment available at all,” said Vasant Narasimhan, global head, drug development and chief medical officer, Novartis. “Novartis confirms its leadership in ophthalmology by entering another new therapy area. The addition of this…

Johnson & Johnson 4Q Sales Drop 2.4 Percent, But U.S. Vision Care Sales Grow

NEW BRUNSWICK, N.J.—Johnson Johnson (NYSE: JNJ) announced sales of $17.8 billion for the fourth quarter of 2015, a decrease of 2.4 percent as compared to the fourth quarter of 2014. Operational sales results increased 4.4 percent and the negative impact of currency was 6.8 percent. Domestic sales increased 8.0 percent. International sales decreased 11.7 percent, reflecting operational growth of 1.2 percent and a negative currency impact of 12.9 percent. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.8 percent, domestic sales increased 13.4 percent and international sales increased 2.9 percent….